Literature DB >> 24858946

Inhibition of protein tyrosine phosphatases enhances cerebral collateral growth in rats.

Ivo Buschmann1, Daniel Hackbusch, Nora Gatzke, André Dülsner, Manuela Trappiel, Markus Dagnell, Arne Ostman, Rob Hooft van Huijsduijnen, Kai Kappert.   

Abstract

UNLABELLED: Arteriogenesis involves the rapid proliferation of preexisting arterioles to fully functional arteries as a compensatory mechanism to overcome circulatory deficits. Stimulation of arteriogenesis has therefore been considered a treatment concept in arterial occlusive disease. Here, we investigated the impact of inhibition of protein tyrosine phosphatases (PTPs) on cerebral arteriogenesis in rats. Arteriogenesis was induced by occlusion of one carotid and both vertebral arteries (three-vessel occlusion (3-VO)). Collateral growth and functional vessel perfusion was assessed 3-35 days following 3-VO. Furthermore, animals underwent 3-VO surgery and were treated with the pan-PTP inhibitor BMOV, the SHP-1 inhibitor sodium stibogluconate (SSG), or the PTP1B inhibitor AS279. Cerebral vessel diameters and cerebrovascular reserve capacity (CVRC) were determined, together with immunohistochemistry analyses and proximity ligation assays (PLA) for determination of tissue proliferation and phosphorylation patterns after 7 days. The most significant changes in vessel diameter increase were present in the ipsilateral posterior cerebral artery (PCA), with proliferative markers (PCNA) being time-dependently increased. The CVRC was lost in the early phase after 3-VO and partially recovered after 21 days. PTP inhibition resulted in a significant increase in the ipsilateral PCA diameter in BMOV-treated animals and rats subjected to PTP1B inhibition. Furthermore, CVRC was significantly elevated in AS279-treated rats compared to control animals, along with hyperphosphorylation of the platelet-derived growth factor-β receptor in the vascular wall in vivo. In summary, our data indicate PTPs as hitherto unrecognized negative regulators in cerebral arteriogenesis. Further, PTP inhibition leading to enhanced collateral growth and blood perfusion suggests PTPs as novel targets in anti-ischemic treatment. KEY MESSAGES: PTPs exhibit negative regulatory function in cerebral collateral growth in rats. Inhibition of pan-PTP/PTP1B increases vessel PDGF-β receptor phosphorylation. PTP1B inhibition enhances arteriogenesis and cerebrovascular reserve capacity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24858946     DOI: 10.1007/s00109-014-1164-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  38 in total

1.  Vascular endothelial growth factor is required for coronary collateral growth in the rat.

Authors:  Eiji Toyota; David C Warltier; Tommy Brock; Erik Ritman; Christopher Kolz; Peter O'Malley; Petra Rocic; Marta Focardi; William M Chilian
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

2.  Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.

Authors:  Elodie Gomez; Magali Vercauteren; Baptiste Kurtz; Antoine Ouvrard-Pascaud; Paul Mulder; Jean-Paul Henry; Marie Besnier; Aurélie Waget; Rob Hooft Van Huijsduijnen; Michel L Tremblay; Remy Burcelin; Christian Thuillez; Vincent Richard
Journal:  J Mol Cell Cardiol       Date:  2012-03-15       Impact factor: 5.000

3.  Therapeutic use of quercetin in the control of infection and anemia associated with visceral leishmaniasis.

Authors:  Gargi Sen; Suparna Mandal; Sudipa Saha Roy; Sibabrata Mukhopadhyay; Tuli Biswas
Journal:  Free Radic Biol Med       Date:  2005-05-01       Impact factor: 7.376

4.  Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation.

Authors:  Kai Kappert; Janna Paulsson; Jan Sparwel; Olli Leppänen; Carina Hellberg; Arne Ostman; Patrick Micke
Journal:  FASEB J       Date:  2006-12-08       Impact factor: 5.191

5.  Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.

Authors:  Andrew N Carr; Michael G Davis; Elaine Eby-Wilkens; Brian W Howard; Bryan A Towne; Thomas E Dufresne; Kevin G Peters
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-02-26       Impact factor: 4.733

6.  Macrophages in collateral arteriogenesis.

Authors:  Erik Fung; Armin Helisch
Journal:  Front Physiol       Date:  2012-09-24       Impact factor: 4.566

7.  Inhibition of protein tyrosine phosphatase improves angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes.

Authors:  Jian-Xiong Chen; Qinhui Tuo; Duan-Fang Liao; Heng Zeng
Journal:  Exp Diabetes Res       Date:  2012-02-12

8.  Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.

Authors:  Thomas Scior; Hans-Georg Mack; José Antonio Guevara García; Wolfhard Koch
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 9.  VEGFA and tumour angiogenesis.

Authors:  L Claesson-Welsh; M Welsh
Journal:  J Intern Med       Date:  2013-02       Impact factor: 8.989

10.  The endothelial tyrosine phosphatase SHP-1 plays an important role for vascular haemostasis in TNFα -induced inflammation in vivo.

Authors:  Elisabeth Koch; Joachim Pircher; Thomas Czermak; Erik Gaitzsch; Stefan Alig; Hanna Mannell; Markus Niemeyer; Florian Krötz; Markus Wörnle
Journal:  Mediators Inflamm       Date:  2013-05-09       Impact factor: 4.711

View more
  2 in total

1.  Bis(maltolato)oxovanadium(IV) Induces Angiogenesis via Phosphorylation of VEGFR2.

Authors:  Laura Parma; Hendrika A B Peters; Maria E Johansson; Saray Gutiérrez; Henk Meijerink; Sjef de Kimpe; Margreet R de Vries; Paul H A Quax
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

2.  Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.

Authors:  Janine Krüger; Ernst Wellnhofer; Heike Meyborg; Philipp Stawowy; Arne Östman; Ulrich Kintscher; Kai Kappert
Journal:  FEBS Open Bio       Date:  2016-01-04       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.